High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring alterations designed to reduce non-specific DNA contacts. SpCas9-HF1 retains on-target activities comparable to wild-type SpCas9 with >85% of single-guide RNAs (sgRNAs) tested in human cells. Notably, with sgRNAs targeted to standard non-repetitive sequences, SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods. Even for atypical, repetitive target sites, the vast majority of off-target mutations induced by wild-type SpCas9 were not detected with SpCas9-HF1. With its exceptional precision, SpCas9-HF1 provides an alternative to wild-type SpCas9 for research and therapeutic applications. More broadly, our results suggest a general strategy for optimizing genome-wide specificities of other CRISPR-RNA-guided nucleases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Precision editing of alleles in a human cell has drastically improved the understanding of genotypic and phenotypic effects in gene therapy due to the lower off-target rates [119,120,121].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To address off-target issues, using the CRISPR system in the form of a rRNP and utilizing high-fidelity CRISPR variants can help minimize off-target effects (Kleinstiver et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kleinstiver et al. developed the high-fidelity SpCas9-HF1, a variant that produced undetectable genome-wide off-target cleavage [134].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, a series of optimized mutations in SpCas9 have greatly improved the editing specificity of Cas9 variants without substantially attenuating the editing activity.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Some active gRNAs for SpCas9-WT showed very low editing ability in SpCas9 variants.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citation
Cited by
Items 701–800 of 1,017
Methods and applications of CRISPR/Cas system for genome editing in stem cells
Yang, G., & Huang, X. (2019) · Cell Regeneration · doi:10.1016/j.cr.2019.08.001 · Cited by 57
Sufyan, M., Daraz, U., Hyder, S., Zulfiqar, U., Iqbal, R., Eldin, S. M., Rafiq, F., Mahmood, N., Shahzad, K., Uzair, M., et al. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01036-w · Cited by 60
“The SpCas9-HF1 is designed to decrease off-target DNA contacts without affecting on-target activity.”
BackgroundInfluentialRecognizing and engineering digital-like logic gates and switches in gene regulatory networks
Bradley, R. W., Buck, M., & Wang, B. (2016) · Current Opinion in Microbiology · doi:10.1016/j.mib.2016.07.004 · Cited by 58
Hematopoietic Stem Cells in Regenerative Medicine: Astray or on the Path?
Müller, A. M., Huppertz, S., & Henschler, R. (2016) · Transfusion Medicine and Hemotherapy · doi:10.1159/000447748 · Cited by 58
Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field
He, Z., Men, K., Qin, Z., Yang, Y., Xu, T., & Wei, Y.-Q. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9033-0 · Cited by 63
CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
Baliou, S., Adamaki, M., Kyriakopoulos, A. M., Spandidos, D. A., Panayiotidis, M. I., Christodoulou, I., & Zoumpourlis, V. C. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4434 · Cited by 66
Mendoza, B. J., & Trinh, C. T. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx564 · Cited by 58
CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges
Cheng, X., Fan, S., Wen, C., & Du, X. (2020) · Briefings in Functional Genomics · doi:10.1093/bfgp/elaa001 · Cited by 59
Genome-wide detection of CRISPR editing in vivo using GUIDE-tag
Liang, S.-Q., Liu, P., Smith, J. L., Mintzer, E., Maitland, S., Dong, X., Yang, Q., Lee, J., Haynes, C. M., Zhu, L. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28135-9 · Cited by 54
Zhou, W., Cui, H., Ying, L., & Yu, X. (2018) · Angewandte Chemie · doi:10.1002/ange.201806941 · Cited by 54
In vivo prime editing rescues alternating hemiplegia of childhood in mice
Sousa, A. A., Terrey, M., Sakai, H. A., Simmons, C. Q., Arystarkhova, E., Morsci, N. S., Anderson, L. C., Xie, J., Suri‐Payer, F., Laux, L. C., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.038 · Cited by 59
Li, L., Jiang, W., & Lü, Y. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.03.007 · Cited by 56
Yuen, K., Wang, Z.-M., Wong, N.-H. M., Zhang, Z., Cheng, T.-F., Lui, W., Chan, C., & Jin, D. (2017) · Virus Research · doi:10.1016/j.virusres.2017.04.019 · Cited by 57
“Genomewide analysis demonstrated that off-target effects were reduced to undetectable levels (Kleinstiver et al., 2016).”
BackgroundYang, H., & Chen, P. (2017) · Virus Research · doi:10.1016/j.virusres.2017.06.010 · Cited by 58
Genomics of Plant Disease Resistance in Legumes
Kankanala, P., Nandety, R. S., & Mysore, K. S. (2019) · Frontiers in Plant Science · doi:10.3389/fpls.2019.01345 · Cited by 57
CRISPR/Cas system: An emerging technology in stem cell research
Valenti, M. T., Serena, M., Carbonare, L. D., & Zipeto, D. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i11.937 · Cited by 62
Lee, J., Sheen, J. H., Lim, O., Lee, Y., Ryu, J., Shin, D., Kim, Y. Y., & Kim, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-74772-9 · Cited by 65
Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD
Himeda, C. L., Jones, T. I., & Jones, P. L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.001 · Cited by 55
Genetic medicines for CF: Hype versus reality
Alton, E. W. F. W., Boyd, A. C., Davies, J. C., Gill, D. R., Griesenbach, U., Harrison, P. T., Henig, N., Higgins, T., Hyde, S. C., Innes, J. A., et al. (2016) · Pediatric Pulmonology · doi:10.1002/ppul.23543 · Cited by 53
The epigenome: the next substrate for engineering
Park, M., Keung, A. J., & Khalil, A. S. (2016) · Genome biology · doi:10.1186/s13059-016-1046-5 · Cited by 61
Rittiner, J. E., Moncalvo, M., Chiba‐Falek, O., & Kantor, B. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00148 · Cited by 62
CRISPR-based strategies in infectious disease diagnosis and therapy
Binnie, A., Fernandes, E., Almeida-Lousada, H., de Mello, R. A., & Castelo‐Branco, P. (2021) · Infection · doi:10.1007/s15010-020-01554-w · Cited by 65
Allemailem, K. S., Almatroodi, S. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Al‐Megrin, W. A. I., Aljamaan, A. N., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087052 · Cited by 62
“Kleinstiver et al. further induced SpCas9-HF1 with other point mutations to generate SpCas9-HF2 (HF1 + D1135E), -HF3 (HF1 + L169A), and -HF4 (HF1 + Y450A).”
BackgroundInfluentialHigh-fidelity, hyper-accurate, and evolved mutants rewire atomic-level communication in CRISPR-Cas9
Skeens, E., Sinha, S., Ahsan, M., D’Ordine, A. M., Jogl, G., Palermo, G., & Lisi, G. P. (2024) · Science Advances · doi:10.1126/sciadv.adl1045 · Cited by 56
“Many notable variants house the majority of their specificity-conferring mutations within the Rec3 domain, including the “high fidelity” Cas9-HF1 ( 4 ), the “hyper-accurate” HypaCas9 ( 3 ), and the “evolved” evoCas9 ( 5 ) variants, suggesting that Rec3 plays a critical role in proofreading the DNA.”
Bjurström, C. F., Mojadidi, M., Phillips, J., Kuo, C., Lai, S., Lill, G. R., Cooper, A., Kaufman, M., Urbinati, F., Wang, X., et al. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.52 · Cited by 55
Bollen, Y., Post, J., Koo, B.-K., & Snippert, H. J. G. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky571 · Cited by 53
“SpCas9, the most widely used class II CRISPR nuclease, primarily recognizes the relatively permissive NGG PAM with limited activity toward NAG PAMs.”
BackgroundInfluentialTaghbalout, A., Du, M., Jillette, N., Rosikiewicz, W., Rath, A., Heinen, C. D., Li, S., & Cheng, A. W. (2019) · Nature Communications · doi:10.1038/s41467-019-12339-7 · Cited by 58
t‐SNAREs bind the Rhg1 α‐SNAP and mediate soybean cyst nematode resistance
Jia, D., Zielinski, R. E., & Hudson, M. E. (2020) · The Plant Journal · doi:10.1111/tpj.14923 · Cited by 53
Lampert, A., Bennett, D., McDermott, L., Neureiter, A., Eberhardt, E., Winner, B., & Zenke, M. (2020) · Neurobiology of Pain · doi:10.1016/j.ynpai.2020.100055 · Cited by 54
Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect
Chuang, Y.-F., Phipps, A. J., Lin, F., Hecht, V. F. G., Hewitt, A. W., Wang, P., & Liu, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03725-2 · Cited by 57
High-level correction of the sickle mutation is amplified in vivo during erythroid differentiation
Magis, W., DeWitt, M. A., Wyman, S. K., Vu, J. T., Heo, S., Shao, S. J., Hennig, F., Romero, Z. G., Campo-Fernández, B., Said, S., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104374 · Cited by 55
“1 (Vakulskas et al., 2018) and Alt-R HiFi Cas9 (Kleinstiver et al., 2016) in healthydonor HSPCs. Error bars depict standard deviation from the mean.”
BackgroundInfluentialGene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation
Ferrari, S., Vavassori, V., Canarutto, D., Jacob, A., Castiello, M. C., Omer, A., & Genovese, P. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618378 · Cited by 57
“1) and SpCas9-HF1] with higher fidelity resulting from dampened interaction strength with the DNA (Kleinstiver et al., 2016; Slaymaker et al., 2016), have been identified by structure-guided mutagenesis.”
BackgroundThe Past, Present, and Future of Genetic Manipulation in Toxoplasma gondii
Wang, J., Huang, S., Behnke, M. S., Chen, K., Shen, B., & Zhu, X. (2016) · Trends in Parasitology · doi:10.1016/j.pt.2016.04.013 · Cited by 58
CRISPR: a versatile tool for both forward and reverse genetics research
Gurumurthy, C. B., Grati, M., Ohtsuka, M., Schilit, S. L. P., Quadros, R. M., & Liu, X. Z. (2016) · Human Genetics · doi:10.1007/s00439-016-1704-4 · Cited by 59
The Power of CRISPR-Cas9-Induced Genome Editing to Speed Up Plant Breeding
Cao, H. X., Wang, W., Hiền, L. T. T., & Vu, G. T. H. (2016) · International Journal of Genomics · doi:10.1155/2016/5078796 · Cited by 58
CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research
Wang, D., Wang, X.-W., Peng, X., Xiang, Y., Song, S.-B., Wang, Y., Chen, L., Xin, V. W., Lyu, Y.-N., Ji, J., et al. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0016-3 · Cited by 54
Strategies for gene disruption and expression in filamentous fungi
Mei, Y., Zhu, Y.-L., Huang, P., Yang, Q., & Dai, C. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09953-2 · Cited by 54
Allele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model
Patrizi, C., Llado, M., Benati, D., Iodice, C., Marrocco, E., Guarascio, R., Surace, E. M., Cheetham, M. E., Auricchio, A., & Recchia, A. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.01.006 · Cited by 47
Precise DNA cleavage using CRISPR-SpRYgests
Christie, K. A., Guo, J. A., Silverstein, R. A., Doll, R. M., Mabuchi, M. Y., Stutzman, H. E., Lin, J., Ma, L., Walton, R. T., Pinello, L., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01492-y · Cited by 56
Self-citationThe economics and policy of genome editing in crop improvement
Kalaitzandonakes, N., Willig, C. J., & Zahringer, K. (2022) · The Plant Genome · doi:10.1002/tpg2.20248 · Cited by 59
“Some variants of Cas9 and Cpf1 have very high sequence specificity (Kleinstiver et al., 2016; Kleinstiver et al., 2019).”
BackgroundInsights into the Mechanism of CRISPR/Cas9-Based Genome Editing from Molecular Dynamics Simulations
Bhattacharya, S., & Satpati, P. (2022) · ACS Omega · doi:10.1021/acsomega.2c05583 · Cited by 58
The expanded CRISPR toolbox for constructing microbial cell factories
Teng, Y., Jiang, T., & Yan, Y. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.06.012 · Cited by 55
Gene therapy and editing: Novel potential treatments for neuronal channelopathies
Wykes, R. C., & Lignani, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.029 · Cited by 55
Moreb, E. A., Hoover, B., Yaseen, A., Valyasevi, N., Roecker, Z. A., Menacho‐Melgar, R., & Lynch, M. (2017) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00174 · Cited by 55
Jeffries, M. A. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.02.001 · Cited by 56
“in 2016 to have nearlyundetectable levels of off-target gene editing [61].”
BackgroundMyotonic Dystrophy and Developmental Regulation of RNA Processing
Thomas, J. D., Oliveira, R., Sznajder, Ł. J., & Swanson, M. S. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170002 · Cited by 55
Clinical applications of CRISPR‐based genome editing and diagnostics
Foss, D. V., Hochstrasser, M. L., & Wilson, R. C. (2019) · Transfusion · doi:10.1111/trf.15126 · Cited by 53
The post-PAM interaction of RNA-guided spCas9 with DNA dictates its target binding and dissociation
Zhang, Q., Wen, F., Zhang, S., Jin, J., Bi, L., Lü, Y., Li, M., Xi, X., Huang, X., Shen, B., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw9807 · Cited by 53
Attenuating apoptosis in Chinese hamster ovary cells for improved biopharmaceutical production
Henry, M. N., MacDonald, M. A., Orellana, C. A., Gray, P. P., Gillard, M., Baker, K. N., Nielsen, L. K., Marcellin, E., Mahler, S. M., & Martínez, V. S. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27269 · Cited by 54
“CRISPR/Cas9 will become a mainstream tool in the near future as workflows become more streamlined, and as precision continues to improve allowing faster validation of apoptotic strategies (Kleinstiver et al., 2016).”
Allosteric regulation of CRISPR-Cas9 for DNA-targeting and cleavage
Zuo, Z., & Liu, J. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.01.013 · Cited by 54
“The mutation positions for each Cas9 variant are marked in the right panel. eSpCas9, SpCas9-HF1, HypaCas9 and SpCas92Pro have been designed by rational approaches, and evoCas9, xCas9 3.7, and Sniper-Cas9 screened through directed evolution.”
BackgroundInfluentialSamuelson, C., Radtke, S., Zhu, H., Llewellyn, M. J., Fields, E., Cook, S. M., Huang, M.-L. W., Jerome, K. R., Kiem, H., & Humbert, O. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.008 · Cited by 54
CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges
Demirci, S., Leonard, A., Haro-Mora, J. J., Uchida, N., & Tisdale, J. F. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2018_331 · Cited by 50
Specificity of oligonucleotide gene therapy (OGT) agents
Nedorezova, D. D., Dubovichenko, M. V., Belyaeva, E. P., Grigorieva, E. D., Peresadina, A. V., & Kolpashchikov, D. M. (2022) · Theranostics · doi:10.7150/thno.77830 · Cited by 54
Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond
Valdmanis, P. N., & Kay, M. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.171 · Cited by 58
Cutting Edge Genetics: CRISPR/Cas9 Editing of Plant Genomes
Soyars, C. L., Peterson, B. A., Burr, C. A., & Nimchuk, Z. L. (2018) · Plant and Cell Physiology · doi:10.1093/pcp/pcy079 · Cited by 55
Initiation of homologous recombination at DNA nicks
Maizels, N., & Davis, L. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky588 · Cited by 55
Raitskin, O., Schudoma, C., West, A., & Patron, N. J. (2019) · PLOS ONE · doi:10.1371/journal.pone.0211598 · Cited by 45
“…have engineered variants of SpCas9 and SaCas9, reportedly reducing their activity at targets to which the spacer does not have 100% identity (39–41 To compare these proteins and determine their function in plants, we measured their efficiency and specificity across a number of targets (Table 2…”
BackgroundVersatile Applications of the CRISPR/Cas Toolkit in Plant Pathology and Disease Management
Wheatley, M. S., & Yang, Y. (2020) · Phytopathology · doi:10.1094/phyto-08-20-0322-ia · Cited by 54
Tran, N. T., Danner, E., Li, X., Graf, R., Lebedin, M., de la Rosa, K., Kühn, R., Rajewsky, K., & Chu, V. T. (2022) · Science Advances · doi:10.1126/sciadv.abm9106 · Cited by 49
Current status of the application of gene editing in pigs
Tanihara, F., Hirata, M., & Otoi, T. (2021) · Journal of Reproduction and Development · doi:10.1262/jrd.2021-025 · Cited by 54
Guide RNAs containing universal bases enable Cas9/Cas12a recognition of polymorphic sequences
Krysler, A. R., Cromwell, C. R., Tu, T., Jovel, J., & Hubbard, B. P. (2022) · Nature Communications · doi:10.1038/s41467-022-29202-x · Cited by 53
Synergistic engineering of CRISPR-Cas nucleases enables robust mammalian genome editing
Chen, Y., Hu, Y., Wang, X., Luo, S., Yang, N., Chen, Y., Li, Z., Zhou, Q., & Li, W. (2022) · The Innovation · doi:10.1016/j.xinn.2022.100264 · Cited by 63
Palacios, A. M., Korus, P., Wilkens, B. G. C., Heshmatpour, N., & Patnaik, S. R. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1342193 · Cited by 56
CRISPR-Cas target recognition for sensing viral and cancer biomarkers
Rahimi, S., Balusamy, S. R., Perumalsamy, H., Ståhlberg, A., & Mijakovic̀, I. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae736 · Cited by 51
“However, specificity of Cas9 can be improved by engineering the enzyme or using truncated sgRNA ( 13 ,14 ).”
BackgroundGenome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease
Hung, S. S. C., McCaughey, T., Swann, O. G., Pébay, A., & Hewitt, A. W. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.05.001 · Cited by 54
Hayes, C. A., Dalia, T. N., & Dalia, A. B. (2017) · Molecular Microbiology · doi:10.1111/mmi.13646 · Cited by 49
Science and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction.
Cribbs, A. P., & Perera, S. (2017) · Oxford University Research Archive (ORA) (University of Oxford) · Cited by 95
Real‐time observation of flexible domain movements in CRISPR–Cas9
Osuka, S., Isomura, K., Kajimoto, S., Komori, T., Nishimasu, H., Shima, T., Nureki, O., & Uemura, S. (2018) · The EMBO Journal · doi:10.15252/embj.201796941 · Cited by 50
CRISPR/Cas9: the Jedi against the dark empire of diseases
Khan, S., Mahmood, M. S., Rahman, S. U., Zafar, H., Khan, S. H., khan, Z., & Ahmad, A. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0425-5 · Cited by 57
Making ends meet: targeted integration of DNA fragments by genome editing
Yamamoto, Y., & Gerbi, S. A. (2018) · Chromosoma · doi:10.1007/s00412-018-0677-6 · Cited by 51
“Recent developments using a high fidelity Cas9 with a few engineered point mutations have further reduced off-target integrations in CRISPR approaches to barely detectable levels (Slaymaker et al. 2016; Kleinstiver et al. 2016).”
BackgroundGene editing of the multi-copy H2A.B gene and its importance for fertility
Anuar, N. D., Kurscheid, S., Field, M. A., Zhang, L., Rebar, E. J., Gregory, P. D., Buchou, T., Bowles, J., Koopman, P. A., Tremethick, D. J., et al. (2019) · Genome biology · doi:10.1186/s13059-019-1633-3 · Cited by 52
Rabai, A., Reisser, L., Reina‐San‐Martin, B., Mamchaoui, K., Cowling, B. S., Nicot, A.-S., & Laporte, J. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.019 · Cited by 52
Tanihara, F., Hirata, M., Nguyen, N. T., Sawamoto, O., Kikuchi, T., Doi, M., & Otoi, T. (2020) · BMC Biotechnology · doi:10.1186/s12896-020-00638-7 · Cited by 50
Self-citationCatalytic-state structure and engineering of Streptococcus thermophilus Cas9
Zhang, Y., Zhang, H., Xu, X., Wang, Y., Chen, W., Wang, Y., Wu, Z., Tang, N., Wang, Y., Zhao, S., et al. (2020) · Nature Catalysis · doi:10.1038/s41929-020-00506-9 · Cited by 51
Using Gene Editing Approaches to Fine-Tune the Immune System
Pavlovic, K., Tristán‐Manzano, M., Maldonado‐Pérez, N., Cortijo-Gutierréz, M., Sánchez-Hernández, S., Justicia-Lirio, P., Carmona-Luque, M. D., Herrera, C., Martín, F., & Benabdellah, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570672 · Cited by 54
“Both CBEs and ABEs have been optimized, resulting in BE variants (Figure 1) with improved efficacy and specificity (32, 37, 38).”
New advances in CRISPR/Cas-mediated precise gene-editing techniques
Richardson, C., Kelsh, R. N., & Richardson, R. J. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049874 · Cited by 57
“…et al., 2020) of the Cas9 PAM preference (Doudna and Charpentier, 2014; Mojica et al., 2009) has likewise increased the spectrum of potential genetic targets, while identification of high-fidelity Cas9 variants has increased specificity (Walton et al., 2020; Kleinstiver et al., 2016, 2015b).”
Application progress of CRISPR/Cas9 genome-editing technology in edible fungi
Zhang, Y., Chen, S., Yang, L., & Zhang, Q. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1169884 · Cited by 54
“, 2016) and high-fidelity-HF1 (SpCas9-HF1) (Kleinstiver et al., 2016).”
Gene correction in patient-specific iPSCs for therapy development and disease modeling
Jang, Y.-Y., & Ye, Z. (2016) · Human Genetics · doi:10.1007/s00439-016-1691-5 · Cited by 55
“More recently, progress has also been made to further improve Cas9 nuclease specificity while retaining the on-target activities, through structure-guided protein engineering (Kleinstiver et al. 2016; Slaymaker et al. 2016).”
BackgroundDeactivated CRISPR Associated Protein 9 for Minor-Allele Enrichment in Cell-Free DNA
Aalipour, A., Dudley, J. C., Park, S.-M., Murty, S., Chabon, J. J., Boyle, E. A., Diehn, M., & Gambhir, S. S. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.278911 · Cited by 50
Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research
Zhen, S., & Li, X. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.063 · Cited by 49
CRISPR/Cas9 System: A Bacterial Tailor for Genomic Engineering
Lone, B. A., Karna, S. K. L., Ahmad, F., Shahi, N., & Pokharel, Y. R. (2018) · Genetics Research International · doi:10.1155/2018/3797214 · Cited by 60
Raikwar, S. P., Kikkeri, N. S., Sakuru, R. C., Saeed, D., Zahoor, H., Premkumar, K., Mentor, S., Thangavel, R., Dubova, I., Ahmed, M. E., et al. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09849-y · Cited by 54
Hulton, C. H., Costa, E. A., Shah, N., Quintanal-Villalonga, À., Heller, G., de Stanchina, E., Rudin, C. M., & Poirier, J. T. (2020) · Nature Cancer · doi:10.1038/s43018-020-0040-8 · Cited by 50
Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases
Yu, W., & Wu, Z. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.011 · Cited by 50
Argonaute proteins: structures and their endonuclease activity
Jin, S., Zhan, J., & Zhou, Y. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06476-w · Cited by 53
Moving toward genome-editing therapies for cardiovascular diseases
Musunuru, K. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148555 · Cited by 51
Concerns regarding ‘off-target’activity of genome editing endonucleases
Kadam, U. S., Shelake, R. M., Chavhan, R. L., & Suprasanna, P. (2018) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2018.03.027 · Cited by 47
van Hees, M., Slott, S., Hansen, A. H., Kim, H. S., Ji, H. P., & Astakhova, K. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.003 · Cited by 47
Engineering of efficiency-enhanced Cas9 and base editors with improved gene therapy efficacies
Yin, S., Zhang, M., Liu, Y., Sun, X., Guan, Y., Chen, X., Yang, L., Huo, Y., Yang, J., Zhang, X., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.014 · Cited by 50
May, D., Paldi, K., & Altpeter, F. (2023) · The Plant Genome · doi:10.1002/tpg2.20298 · Cited by 50
“Other engineered variants of SpCas9, including “enhanced specificity” SpCas9 (eSpCas9) (Slaymaker et al., 2016) and high-fidelity1 SpCas9 (Cas9-HF1) (Kleinstiver et al., 2016), were selected for lower off-target activity; their applicability for multiallelic gene editing was confirmed in potato…”
BackgroundCRISPR-Editing Therapy for Duchenne Muscular Dystrophy
Chemello, F., Olson, E. N., & Bassel‐Duby, R. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.053 · Cited by 53
CRISPR/Cas-Based Diagnostics in Agricultural Applications
Tanny, T., Sallam, M., Soda, N., Nguyen, N., Alam, M. M., & Shiddiky, M. J. A. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c00913 · Cited by 48
Self-citationPAM-flexible Engineered FnCas9 variants for robust and ultra-precise genome editing and diagnostics
Acharya, S., Ansari, A. H., Das, P. K., Hirano, S., Aich, M., Rauthan, R., Mahato, S., Maddileti, S., Sarkar, S., Kumar, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49233-w · Cited by 51
Goodman, M., & Malik, P. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716653729 · Cited by 53
CRISPR/Cas9: A Practical Approach in Date Palm Genome Editing
Sattar, M. N., Iqbal, Z., Tahir, M. N., Shahid, M. S., Khurshid, M., Al-Khateeb, A. A., & Al-Khateeb, S. A. (2017) · Frontiers in Plant Science · doi:10.3389/fpls.2017.01469 · Cited by 51
The Chromatin Structure Differentially Impacts High-Specificity CRISPR-Cas9 Nuclease Strategies
Chen, X., Liu, J., Janssen, J. M., & Gonçalves, M. A. F. V. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.08.005 · Cited by 49
Bridge Helix of Cas9 Modulates Target DNA Cleavage and Mismatch Tolerance
Babu, K., Amrani, N., Jiang, W., Yogesha, S. D., Nguyen, R., Qin, P. Z., & Rajan, R. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01241 · Cited by 49
Mobile Introns Shape the Genetic Diversity of Their Host Genes
Repar, J., & Warnecke, T. (2017) · Genetics · doi:10.1534/genetics.116.199059 · Cited by 63
“The principal concern here has been to identify and reduce off-target activity (Cho et al. 2014; Kleinstiver et al. 2016).”
BackgroundMultiplex nucleotide editing by high-fidelity Cas9 variants with improved efficiency in rice
Xu, W., Song, W., Yang, Y., Wu, Y., Lv, X., Yuan, S., Liu, Y., & Yang, J. (2019) · BMC Plant Biology · doi:10.1186/s12870-019-2131-1 · Cited by 47
“diminishing the ability to cleave mismatched off-target sites [25].”
BackgroundJiang, L., Ingelshed, K., Shen, Y., Boddul, S. V., Iyer, V. S., Kasza, Z., Sedimbi, S. K., Lane, D. P., & Wermeling, F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1692 · Cited by 51
Metadata
- Authors
- Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- City University of Hong Kong (HK)
- Corresponding author
- Joung, J. Keith
- ORCID
- Venue
- Nature
- Published
- 2016-01-06
- Volume
- 529
- Issue
- 7587
- Pages
- 490-495
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4851738
- OpenAlex
- W2224398381
- Cited by
- 2,673
- References
- 47
- Citations by year
- 2026: 189 · 2025: 221 · 2024: 200 · 2023: 181 · 2022: 267 · 2021: 273 · 2020: 287 · 2019: 284 · 2018: 284 · 2017: 267 · 2016: 215
- FWCI
- 181.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM107427, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, off-target mutations, Streptococcus pyogenes, single guide RNA, targeted sequencing, genome editing
- MeSH terms
- Base Sequence, DNA, DNA-Binding Proteins, Endonucleases, Genetic Engineering, Humans, Mutation, Protein Binding, RNA, Streptococcus pyogenes, Substrate Specificity, Reproducibility of Results, Genome, Human, Sequence Analysis, DNA, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.